Curative approaches for sickle cell disease: A review of allogeneic and autologous strategies.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Blood Cells, Molecules & Diseases

• Publication date

  2017-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.bcmd.2017.08.014PMID 28893518
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation.

  2017cited by this paper
• Gene Therapy in a Patient with Sickle Cell Disease: Brief Report

  2017cited by this paper
• Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells

  2016cited by this paper
• Gene Therapy for Hemoglobinopathies: Tremendous Successes and Remaining Caveats.

  2016cited by this paper
• Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia

  2016cited by this paper
• Enhanced in utero allogeneic engraftment in mice after mobilizing fetal HSCs by α4β1/7 inhibition.

  2016cited by this paper
• In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration

  2016cited by this paper
• Interim Results from a Phase 1/2 Clinical Study of Lentiglobin Gene Therapy for Severe Sickle Cell Disease

  2016cited by this paper
• A trial of unrelated donor marrow transplantation for children with severe sickle cell disease.

  2016cited by this paper
• Forced chromatin looping raises fetal hemoglobin in adult sickle cells to higher levels than pharmacologic inducers.

  2016cited by this paper
• Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease.

  2016cited by this paper
• Bcl11a Deficiency Leads to Hematopoietic Stem Cell Defects with an Aging-like Phenotype.

  2016cited by this paper
• Optimizing autologous cell grafts to improve stem cell gene therapy.

  2016cited by this paper
• Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin

  2016cited by this paper
• Krüppeling erythropoiesis: an unexpected broad spectrum of human red blood cell disorders due to KLF1 variants.

  2016cited by this paper
• CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells

  2016cited by this paper
• A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition

  2016cited by this paper
• Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin

  2016cited by this paper
• BCL11A Haploinsufficiency Causes an Intellectual Disability Syndrome and Dysregulates Transcription

  2016cited by this paper
• Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease.

  2016cited by this paper
• Fetal haemoglobin in sickle-cell disease: from genetic epidemiology to new therapeutic strategies.

  2016cited by this paper
• Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the βA(T87Q)-Globin Gene

  2016cited by this paper
• Mathematical modeling of erythrocyte chimerism informs genetic intervention strategies for sickle cell disease

  2016cited by this paper
• Strict in vivo specificity of the Bcl11a erythroid enhancer.

  2016cited by this paper
• Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype.

  2016cited by this paper
• Defining and improving the genome-wide specificities of CRISPR–Cas9 nucleases

  2016cited by this paper
• Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage

  2016cited by this paper
• Survival among children and adults with sickle cell disease in Belgium: Benefit from hydroxyurea treatment

  2015cited by this paper
• Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies

  2015cited by this paper
• Potentially therapeutic levels of anti-sickling globin gene expression following lentivirus-mediated gene transfer in sickle cell disease bone marrow CD34+ cells.

  2015cited by this paper
• Initial Results from Study Hgb-206: A Phase 1 Study Evaluating Gene Therapy By Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the Lentiglobin BB305 Lentiviral Vector in Subjects with Severe Sickle Cell Disease

  2015cited by this paper
• Editing the genome to introduce a beneficial naturally occurring mutation associated with increased fetal globin

  2015cited by this paper
• Bench to Bedside-Gene Therapy for Thalassemia and Sickle Cell Disease

  2015cited by this paper
• Outcomes of Gene Therapy for Severe Sickle Disease and Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex Vivo with a Lentiviral Beta AT87Q-Globin Vector

  2015cited by this paper
• miRNA-embedded shRNAs for Lineage-specific BCL11A Knockdown and Hemoglobin F Induction.

  2015cited by this paper
• Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells.

  2015cited by this paper
• BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis

  2015cited by this paper
• BCL11A deletions result in fetal hemoglobin persistence and neurodevelopmental alterations.

  2015cited by this paper
• Gene therapy returns to centre stage

  2015cited by this paper
• 2p15-p16.1 microdeletions encompassing and proximal to BCL11A are associated with elevated HbF in addition to neurologic impairment.

  2015cited by this paper
• Single-cell transcriptomic reconstruction reveals cell cycle and multi-lineage differentiation defects in Bcl11a-deficient hematopoietic stem cells

  2015cited by this paper
• Treosulfan‐based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease

  2015cited by this paper
• Don’t edit the human germ line

  2015cited by this paper
• A prudent path forward for genomic engineering and germline gene modification

  2015cited by this paper
• Xenograft models for normal and malignant stem cells.

  2015cited by this paper
• Homology-driven genome editing in hematopoietic stem and progenitor cells using zinc finger nuclease mRNA and AAV6 donors

  2015cited by this paper
• Whole Organism Genome Editing: Targeted Large DNA Insertion via ObLiGaRe Nonhomologous End-Joining in Vivo Capture

  2015cited by this paper
• Concise Review: Lessons Learned From Clinical Trials of Gene Therapy in Monogenic Immunodeficiency Diseases

  2014cited by this paper
• Reactivation of developmentally silenced globin genes by forced chromatin looping.

  2014cited by this paper
• Preclinical Evaluation of Efficacy and Safety of an Improved Lentiviral Vector for the Treatment of β-Thalassemia and Sickle Cell Disease

  2014cited by this paper
• Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery

  2014cited by this paper
• Targeted Genome Editing in Human Repopulating Hematopoietic Stem Cells

  2014cited by this paper
• Gene Therapy for Wiskott-Aldrich Syndrome—Long-Term Efficacy and Genotoxicity

  2014cited by this paper
• Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.

  2014cited by this paper
• Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease

  2014cited by this paper
• Characterization of Genomic Deletion Efficiency Mediated by Clustered Regularly Interspaced Palindromic Repeats (CRISPR)/Cas9 Nuclease System in Mammalian Cells*♦

  2014cited by this paper
• Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

  2014cited by this paper
• Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells.

  2014cited by this paper
• β-globin gene transfer to human bone marrow for sickle cell disease.

  2013cited by this paper
• Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease.

  2013cited by this paper
• Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy

  2013cited by this paper
• Umbilical Cord Blood: An Evolving Stem Cell Source for Sickle Cell Disease Transplants

  2013cited by this paper
• Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling.

  2013cited by this paper
• An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level

  2013cited by this paper
• Stem cell transplantation after reduced‐intensity conditioning for sickle cell disease

  2013cited by this paper
• Broadening the indications for hematopoietic stem cell genetic therapies.

  2013cited by this paper
• Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease.

  2013cited by this paper
• HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease.

  2012cited by this paper
• Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).

  2012cited by this paper
• Stem cell transplantation for treatment of sickle cell disease: bone marrow versus cord blood transplants.

  2012cited by this paper
• Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide.

  2011cited by this paper
• Umbilical cord blood transplantation for children with thalassemia and sickle cell disease.

  2011cited by this paper
• MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13

  2011cited by this paper
• Cord blood transplantation in patients with hemoglobinopathies.

  2010cited by this paper
• Umbilical cord blood transplantation for thalassemia major.

  2010cited by this paper
• Successful unrelated donor cord blood transplantation for adult sickle cell disease and Hodgkin lymphoma

  2010cited by this paper
• Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis.

  2010cited by this paper
• Stem-cell gene therapy for the Wiskott-Aldrich syndrome.

  2010cited by this paper
• Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease

  2010cited by this paper
• Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia

  2010cited by this paper
• Hematopoietic stem cell mobilization strategies for gene therapy of beta thalassemia and sickle cell disease

  2010cited by this paper
• Transcriptional enhancers induce insertional gene deregulation independently from the vector type and design.

  2009cited by this paper
• A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction.

  2009cited by this paper
• Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?

  2009cited by this paper
• Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors.

  2009cited by this paper
• The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy.

  2009cited by this paper
• Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy

  2009cited by this paper
• Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region.

  2009cited by this paper
• Cord blood stem cell transplantation for haemoglobinopathies

  2008cited by this paper
• Improved survival of children and adolescents with sickle cell disease.

  2008cited by this paper
• Physiological promoters reduce the genotoxic risk of integrating gene vectors.

  2008cited by this paper
• DNA polymorphisms at the BCL11A, HBS1L-MYB, and β-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease

  2008cited by this paper
• Globin Lentiviral Vector Insertions Can Perturb the Expression of Endogenous Genes in β-thalassemic Hematopoietic Cells.

  2008cited by this paper
• Combinatorial Incorporation of Enhancer‐Blocking Components of the Chicken β‐Globin 5′HS4 and Human T‐Cell Receptor α/δ BEAD‐1 Insulators in Self‐Inactivating Retroviral Vectors Reduces Their Genotoxic Potential

  2008cited by this paper
• Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.

  2008cited by this paper
• HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

  2008cited by this paper
• In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of β-thalassemia

  2008cited by this paper
• Unrelated cord blood transplantation in children with sickle cell disease: Review of four‐center experience

  2007cited by this paper
• Efficient Transplantation via Antibody-Based Clearance of Hematopoietic Stem Cell Niches

  2007cited by this paper
• Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease.

  2007cited by this paper

• Integrating sickle cell disease care into primary healthcare in Uganda: a narrative review

  2025cites this paper
• A systematic review comparing allogeneic hematopoietic stem cell transplant to gene therapy in sickle cell disease

  2023influential citation
• Sideroblastic anaemia in a patient with sickle cell disease

  2022cites this paper
• Stem cells in the treatment of sickle cell disease

  2020cites this paper
• In Vivo Outcome of Homology-Directed Repair at the HBB Gene in HSC Using Alternative Donor Template Delivery Methods

  2019cites this paper
• Health-Related Quality of Life and Personal Life Goals of Adults With Sickle Cell Disease After Hematopoietic Stem Cell Transplantation

  2019cites this paper
• Rational targeting of a NuRD subcomplex guided by comprehensive in situ mutagenesis

  2019cites this paper
• The experience of adults with sickle cell disease and their HLA-matched adult sibling donors after allogeneic hematopoietic stem cell transplantation.

  2019cites this paper
• Choice of Donor Source and Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Sickle Cell Disease

  2019cites this paper
• Simple chronic transfusion therapy, a crucial therapeutic option for sickle cell disease, improves but does not normalize blood rheology: What should be our goals for transfusion therapy?

  2018cites this paper
• The in vitro growth of a cord blood-derived cell population enriched for CD34+ cells is influenced by its cell cycle status and treatment with hydroxyurea.

  2018cites this paper
• Fetal hemoglobin induction in sickle erythroid progenitors using a synthetic zinc finger DNA-binding domain

  2018cites this paper
• Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons.

  2018cites this paper
• Primary Care of Patients with Sickle Cell Disease

  2017cites this paper